<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Date of report (Date of earliest event
reported): <U> &#9;February 12, 2012&#9;</U></B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>SeraCare Life Sciences, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact Name of Registrant as Specified in
Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Delaware</B></P></TD>
    <TD STYLE="width: 5%; padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>001-34105</B></P></TD>
    <TD STYLE="width: 5%; padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>33-0056054</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of incorporation) </B></P></TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; font-weight: bold; text-align: center">(Commission file number)</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>37 Birch Street, Milford, Massachusetts
01757</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Registrant&rsquo;s telephone number,
including area code: <B><U>&#9;(508) 244-6400&#9;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>&#9;Not Applicable&#9;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">x</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.142-12)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white"><FONT STYLE="background-color: white"><B>Item
1.01&#9;Entry into a Material Definitive Agreement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Agreement and Plan of Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 12, 2012, SeraCare Life Sciences,
Inc., a Delaware corporation (the &ldquo;Company&rdquo;), entered into an Agreement and Plan of Merger (the &ldquo;Merger Agreement&rdquo;)
with Project Plasma Holdings Corporation, a Delaware corporation (&ldquo;Parent&rdquo;), and Project Plasma Merger Corp., a Delaware
corporation and a wholly owned subsidiary of Parent (&ldquo;Merger Sub&rdquo;), providing for the merger of Merger Sub with and
into the Company (the &ldquo;Merger&rdquo;), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Parent
and Merger Sub are affiliates of Linden Capital Partners. The Merger Agreement was unanimously approved by the Company&rsquo;s
Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">At the effective time of the Merger, each share
of Company common stock issued and outstanding immediately prior to the effective time (other than shares (i) held by the Company
in treasury, (ii) owned by Parent or Merger Sub or any other wholly owned subsidiary of Parent, or (iii) held by shareholders who
have perfected and not withdrawn a demand for appraisal rights under Delaware law) will be cancelled and converted automatically
into the right to receive $4.00 in cash (the &ldquo;Per Share Merger Consideration&rdquo;), without interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Consummation of the Merger is subject to various
closing conditions, including (i) the adoption of the Merger Agreement by the holders of a majority of the outstanding shares of
the Company&rsquo;s common stock entitled to vote on the Merger (the &ldquo;Shareholder Approval&rdquo;), (ii) the expiration or
early termination of the waiting period applicable to the consummation of the Merger under the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended, and (iii) no governmental entity having enacted, issued, promulgated or granted any order, judgment, decision,
decree, injunction, ruling, writ or assessment or statute, law, constitution, treaty, convention, ordinance, code, rule or regulation
that has the effect of making the Merger illegal or of prohibiting or otherwise preventing the consummation of the Merger in the
United States. Moreover, each party&rsquo;s obligation to consummate the Merger is subject to certain other conditions, including
(i) the accuracy of the other party&rsquo;s representations and warranties contained in the Merger Agreement (subject to materiality
exceptions) and (ii) the other party&rsquo;s performance in all material respects of all obligations required to be performed by
it under the Merger Agreement on or prior to the closing date. In addition, the obligation of Parent and Merger Sub to consummate
the Merger is subject to the non-occurrence of any condition, circumstance, event, change, occurrence, state of facts or effect
that has had or would reasonably be expected to have a material adverse effect on the business, financial condition, assets or
results of operations of the Company or the ability of the Company to perform its obligations under the Merger Agreement or to
consummate the Merger and the other transactions contemplated by the Merger Agreement (subject to various exceptions). Consummation
of the Merger is not subject to a financing condition. If the Merger is not consummated by July 16, 2012, either party generally
has the right to terminate the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Parent and Merger Sub have obtained a financing
commitment for the transaction contemplated by the Merger Agreement. Subject to the terms and conditions set forth in the financing
commitment, funds affiliated with Linden Capital Partners (the &ldquo;Sponsors&rdquo;) have committed to invest, directly or indirectly,
at or immediately prior to the consummation of the Merger, $82.0 million in Parent or Merger Sub, solely for the purpose of (i)
funding the aggregate Per Share Merger Consideration and (ii) paying all related fees and expenses pursuant to, and in accordance
with, the Merger Agreement. The aggregate proceeds from the financing commitment are expected to be sufficient for Parent to finance
the transactions contemplated by the Merger Agreement. The Sponsors have also agreed to guarantee certain obligations of Parent
and Merger Sub under the Merger Agreement, on the terms and subject to the conditions set forth in a sponsor guarantee in favor
of the Company, including the payment of any reverse termination fee and specified costs and expenses that may become payable by
Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company has made various representations,
warranties and covenants in the Merger Agreement, including covenants regarding: (i) the conduct of the business of the Company
prior to the consummation of the Merger, (ii) the calling and holding of a meeting of the Company&rsquo;s shareholders for the
purpose of obtaining the Shareholder Approval and (iii) the use of reasonable best efforts to cause the Merger to be consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under the Merger Agreement, the Company is subject
to a &ldquo;no-shop&rdquo; restriction on its ability to solicit offers or proposals relating to an alternative acquisition proposal
or to provide information to or engage in discussions or negotiations with third parties regarding an alternative acquisition proposal.
However, the no-shop provision is subject to a &ldquo;fiduciary-out&rdquo; provision that allows the Company under certain circumstances,
prior to receipt of the Shareholder Approval, and subject to certain conditions, to provide information to and participate in discussions
with third parties with respect to certain unsolicited written alternative acquisition proposals if the Company&rsquo;s Board of
Directors has determined, after consultation with its financial advisor and outside counsel, and taking into account all relevant
factors, that such alternative acquisition proposal would, if consummated, result in a transaction more favorable to the Company&rsquo;s
shareholders than the transactions contemplated by the Merger Agreement and is reasonably capable of being completed on the terms
proposed, and not doing so would reasonably be expected to be inconsistent with its fiduciary duties under applicable law. The
Merger Agreement provides Parent certain rights to match any such superior proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Merger Agreement contains certain termination
rights for the Company and Parent. Upon termination of the Merger Agreement under specified circumstances, the Company may be required
to pay Parent a termination fee of $2.5 million, including upon acceptance of a superior proposal, or to reimburse Parent for up
to $1.0 million of its out-of-pocket expenses in connection with the transaction. The Merger Agreement also provides that Parent
will be required to pay the Company a reverse termination fee of $5.0 million under specified circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The representations, warranties and covenants
of the Company contained in the Merger Agreement have been made solely for the benefit of Parent and Merger Sub. In addition, such
representations, warranties and covenants (i) have been made only for purposes of the Merger Agreement, (ii) have been qualified
by (a) matters specifically disclosed in any reports filed by the Company with the Securities and Exchange Commission since October
1, 2009 and (b) confidential disclosures made to Parent and Merger Sub in connection with the Merger Agreement, (iii) are subject
to materiality qualifications contained in the Merger Agreement which may differ from what may be viewed as material by investors,
(iv) were made only as of the date of the Merger Agreement or such other date as is specified in the Merger Agreement, and (v)
have been included in the Merger Agreement for the purpose of allocating risk between the contracting parties rather than establishing
matters as facts. Accordingly, the Merger Agreement is included with this filing only to provide investors with information regarding
the terms of the Merger Agreement, and not to provide investors with any other factual information regarding the Company or its
business. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations
of the actual state of facts or condition of the Company or any of its affiliates. Moreover, information concerning the subject
matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may
or may not be fully reflected in the Company&rsquo;s public disclosures. The Merger Agreement should not be read alone, but should
instead be read in conjunction with the other information regarding the Company that is or will be contained in, or incorporated
by reference into, the annual, quarterly and current reports and other documents that the Company files or has filed with the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The foregoing description of the Merger Agreement
and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by,
the full text of the Merger Agreement attached hereto as Exhibit 2.1, which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Indemnification Agreements </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 12, 2012, the Board of Directors
of the Company authorized the Company to enter into indemnification agreements in the form attached as Exhibit 10.1 hereto (the
&ldquo;Indemnification Agreements&rdquo;) with each of its directors and its Interim President and Chief Executive Officer and
Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each Indemnification Agreement provides, among
other things, that, subject to the procedures set forth in the Indemnification Agreement: (i) the Company will indemnify the director
or officer in connection with any action, suit, arbitration, alternative dispute resolution proceeding, administrative hearing
or other proceeding arising after the date of the agreement as to which the director or officer is, was or is threatened to be
made a party (or is otherwise involved) by reason of such director&rsquo;s or officer&rsquo;s status as a director or officer of
the Company or in certain other capacities, to the fullest extent permitted by law; (ii) if requested by the director or officer,
and subject to specified exceptions, the Company will advance expenses to the director or officer in connection with any such proceeding;
(iii) if there is a change in control, upon the director&rsquo;s or officer&rsquo;s written election, the Company will seek the
advice of independent legal counsel with respect to whether such director or officer has met the applicable standard of conduct
to be entitled to indemnification under the Indemnification Agreement and such director&rsquo;s or officer&rsquo;s right to advancement
of expenses; and (iv) the rights of the director or officer under the Indemnification Agreement are in addition to any other rights
the director or officer may have under the Company&rsquo;s certificate of incorporation or by-laws or the General Corporation Law
of the State of Delaware or otherwise. In addition, each Indemnification Agreement establishes procedures regarding the defense
and settlement of claims by the parties, the relevant burden of proof and the period of limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The foregoing summary of the Indemnification
Agreements is qualified in its entirety by reference to the full text of the form of Indemnification Agreement attached as Exhibit
10.1 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Cautionary Statement Regarding Forward-Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We caution you that this document may contain
disclosures that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about
the Company and the Merger. Forward-looking statements include statements in which we use words such as &quot;expect,&quot; &quot;believe,&quot;
&quot;anticipate,&quot; &quot;intend,&quot; or similar expressions. These forward-looking statements are based upon information
presently available to the Company&rsquo;s management and are inherently subjective, uncertain and subject to change, due to any
number of risks and uncertainties. Factors that could cause events not to occur as expressed in the forward-looking statements
in this document include, but are not limited to, unanticipated delays; the occurrence of any event, change or other circumstances
that could give rise to the termination of the Merger Agreement; the outcome of any legal proceedings that may be instituted with
respect to the Merger; and the inability to complete the Merger due to the failure to obtain the Shareholder Approval or the failure
to satisfy other closing conditions, including the receipt of required regulatory approvals, as well as other risk factors detailed
in the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on November 21, 2011, as amended, under the captions &ldquo;Cautionary
Note Regarding Forward-Looking Statements&rdquo; and &ldquo;Risk Factors&rdquo; and otherwise in the Company&rsquo;s reports and
filings with the Securities and Exchange Commission. Many of these factors are beyond the Company&rsquo;s ability to control or
predict. You should not place undue reliance on any forward-looking statements, since those statements speak only as of the date
that they are made. The Company assumes no obligation to update, revise or correct any forward-looking statements after the date
of this document or after the respective dates on which such statements otherwise are made, whether as a result of new information,
future events or otherwise, except as otherwise may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Additional Information about the Merger and Where to Find
It</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This document may be deemed to be solicitation
material with respect to the Merger. In connection with the Merger, the Company intends to file a preliminary proxy statement and
file or furnish other relevant materials with the Securities and Exchange Commission, or the SEC. Once the SEC completes its review
of the preliminary proxy statement, a definitive proxy statement and a form of proxy will be filed with the SEC and mailed to the
shareholders of the Company. THE COMPANY&rsquo;S INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY
ALL RELEVANT MATERIALS FILED OR FURNISHED WITH THE SEC, INCLUDING THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE, BECAUSE THESE
MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE MERGER. The proxy statement and other
relevant materials (when they become available), and any and all documents filed or furnished by the Company with or to the SEC,
may be obtained free of charge at the SEC&rsquo;s web site at www.sec.gov. In addition, the Company&rsquo;s investors and security
holders may obtain free copies of the documents filed or furnished by the Company with or to the SEC by directing a written request
to SeraCare Life Sciences, Inc., 37 Birch Street, Milford, MA 01757, Attention: Corporate Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Participants in the Solicitation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company and its executive officers and directors
may be deemed to be participants in the solicitation of proxies from the shareholders of the Company with respect to the special
meeting of shareholders that will be held to consider the Merger. Information about those executive officers and directors of the
Company and their ownership of the Company&rsquo;s common stock is set forth in Amendment No. 1 to the Company&rsquo;s Annual Report
on Form 10-K for the fiscal year ended September 30, 2011, which was filed with the SEC on January 30, 2012, and is supplemented
by other public filings made, and to be made, with the SEC by the Company. Information regarding the direct and indirect interests
of the Company, its executive officers and directors and other participants in the solicitation, which may, in some cases, be different
from those of the Company&rsquo;s security holders generally, will be set forth in the proxy statement relating to the Merger when
it becomes available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">(d) &#9;<U>Exhibits</U>.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font-size: 10pt; font-weight: bold; text-decoration: underline">Exhibit No.</TD>
    <TD STYLE="width: 85%; font-size: 10pt; font-weight: bold; text-decoration: underline">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">2.1</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc.*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">10.1</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Form of Indemnification Agreement with members of the Board of Directors and the Interim President and Chief Executive Officer and Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">__________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* Schedules have been omitted pursuant to Item 601(b)(2) of Regulation
S-K. SeraCare Life Sciences, Inc. hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request
by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">SERACARE LIFE SCIENCES, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">By: <U> /s/ Gregory A. Gould&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">Name: Gregory A. Gould</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">Title: &nbsp;&nbsp;Interim President and Chief
Executive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Officer, Chief Financial Officer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Secretary
and Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dated: February 14, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; width: 15%">Exhibit No.</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; width: 85%">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">2.1</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc.*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">10.1</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Form of Indemnification Agreement with members of the Board of Directors and the Interim President and Chief Executive Officer and Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* Schedules have been omitted pursuant to Item 601(b)(2) of Regulation
S-K. SeraCare Life Sciences, Inc. hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request
by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v302363_8-k.htm", "secsgml_size_bytes": 37801}]
{"company-data": {"conformed-name": "SERACARE LIFE SCIENCES INC", "cik": "0001156295", "assigned-sic": "2835", "irs-number": "330056054", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-34105", "film-number": "12612647"}, "business-address": {"street1": "37 BIRCH STREET", "city": "MILFORD", "state": "MA", "zip": "01757", "phone": "5082446400"}, "mail-address": {"street1": "37 BIRCH STREET", "city": "MILFORD", "state": "MA", "zip": "01757"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported):
February 12, 2012
SeraCare Life Sciences, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
001-34105
33-0056054
(State or other jurisdiction
of incorporation)
(Commission file number)
(IRS Employer
Identification No.)
37 Birch Street, Milford, Massachusetts
01757
(Address of principal executive offices)
Registrant's telephone number,
including area code:
(508) 244-6400
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
x
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.142-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.01	Entry into a Material Definitive Agreement.
Agreement and Plan of Merger
On February 12, 2012, SeraCare Life Sciences,
Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement")
with Project Plasma Holdings Corporation, a Delaware corporation ("Parent"), and Project Plasma Merger Corp., a Delaware
corporation and a wholly owned subsidiary of Parent ("Merger Sub"), providing for the merger of Merger Sub with and
into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Parent
and Merger Sub are affiliates of Linden Capital Partners. The Merger Agreement was unanimously approved by the Company's
Board of Directors.
At the effective time of the Merger, each share
of Company common stock issued and outstanding immediately prior to the effective time (other than shares (i) held by the Company
in treasury, (ii) owned by Parent or Merger Sub or any other wholly owned subsidiary of Parent, or (iii) held by shareholders who
have perfected and not withdrawn a demand for appraisal rights under Delaware law) will be cancelled and converted automatically
into the right to receive $4.00 in cash (the "Per Share Merger Consideration"), without interest.
Consummation of the Merger is subject to various
closing conditions, including (i) the adoption of the Merger Agreement by the holders of a majority of the outstanding shares of
the Company's common stock entitled to vote on the Merger (the "Shareholder Approval"), (ii) the expiration or
early termination of the waiting period applicable to the consummation of the Merger under the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended, and (iii) no governmental entity having enacted, issued, promulgated or granted any order, judgment, decision,
decree, injunction, ruling, writ or assessment or statute, law, constitution, treaty, convention, ordinance, code, rule or regulation
that has the effect of making the Merger illegal or of prohibiting or otherwise preventing the consummation of the Merger in the
United States. Moreover, each party's obligation to consummate the Merger is subject to certain other conditions, including
(i) the accuracy of the other party's representations and warranties contained in the Merger Agreement (subject to materiality
exceptions) and (ii) the other party's performance in all material respects of all obligations required to be performed by
it under the Merger Agreement on or prior to the closing date. In addition, the obligation of Parent and Merger Sub to consummate
the Merger is subject to the non-occurrence of any condition, circumstance, event, change, occurrence, state of facts or effect
that has had or would reasonably be expected to have a material adverse effect on the business, financial condition, assets or
results of operations of the Company or the ability of the Company to perform its obligations under the Merger Agreement or to
consummate the Merger and the other transactions contemplated by the Merger Agreement (subject to various exceptions). Consummation
of the Merger is not subject to a financing condition. If the Merger is not consummated by July 16, 2012, either party generally
has the right to terminate the Merger Agreement.
Parent and Merger Sub have obtained a financing
commitment for the transaction contemplated by the Merger Agreement. Subject to the terms and conditions set forth in the financing
commitment, funds affiliated with Linden Capital Partners (the "Sponsors") have committed to invest, directly or indirectly,
at or immediately prior to the consummation of the Merger, $82.0 million in Parent or Merger Sub, solely for the purpose of (i)
funding the aggregate Per Share Merger Consideration and (ii) paying all related fees and expenses pursuant to, and in accordance
with, the Merger Agreement. The aggregate proceeds from the financing commitment are expected to be sufficient for Parent to finance
the transactions contemplated by the Merger Agreement. The Sponsors have also agreed to guarantee certain obligations of Parent
and Merger Sub under the Merger Agreement, on the terms and subject to the conditions set forth in a sponsor guarantee in favor
of the Company, including the payment of any reverse termination fee and specified costs and expenses that may become payable by
Parent.
The Company has made various representations,
warranties and covenants in the Merger Agreement, including covenants regarding: (i) the conduct of the business of the Company
prior to the consummation of the Merger, (ii) the calling and holding of a meeting of the Company's shareholders for the
purpose of obtaining the Shareholder Approval and (iii) the use of reasonable best efforts to cause the Merger to be consummated.
Under the Merger Agreement, the Company is subject
to a "no-shop" restriction on its ability to solicit offers or proposals relating to an alternative acquisition proposal
or to provide information to or engage in discussions or negotiations with third parties regarding an alternative acquisition proposal.
However, the no-shop provision is subject to a "fiduciary-out" provision that allows the Company under certain circumstances,
prior to receipt of the Shareholder Approval, and subject to certain conditions, to provide information to and participate in discussions
with third parties with respect to certain unsolicited written alternative acquisition proposals if the Company's Board of
Directors has determined, after consultation with its financial advisor and outside counsel, and taking into account all relevant
factors, that such alternative acquisition proposal would, if consummated, result in a transaction more favorable to the Company's
shareholders than the transactions contemplated by the Merger Agreement and is reasonably capable of being completed on the terms
proposed, and not doing so would reasonably be expected to be inconsistent with its fiduciary duties under applicable law. The
Merger Agreement provides Parent certain rights to match any such superior proposal.
The Merger Agreement contains certain termination
rights for the Company and Parent. Upon termination of the Merger Agreement under specified circumstances, the Company may be required
to pay Parent a termination fee of $2.5 million, including upon acceptance of a superior proposal, or to reimburse Parent for up
to $1.0 million of its out-of-pocket expenses in connection with the transaction. The Merger Agreement also provides that Parent
will be required to pay the Company a reverse termination fee of $5.0 million under specified circumstances.
The representations, warranties and covenants
of the Company contained in the Merger Agreement have been made solely for the benefit of Parent and Merger Sub. In addition, such
representations, warranties and covenants (i) have been made only for purposes of the Merger Agreement, (ii) have been qualified
by (a) matters specifically disclosed in any reports filed by the Company with the Securities and Exchange Commission since October
1, 2009 and (b) confidential disclosures made to Parent and Merger Sub in connection with the Merger Agreement, (iii) are subject
to materiality qualifications contained in the Merger Agreement which may differ from what may be viewed as material by investors,
(iv) were made only as of the date of the Merger Agreement or such other date as is specified in the Merger Agreement, and (v)
have been included in the Merger Agreement for the purpose of allocating risk between the contracting parties rather than establishing
matters as facts. Accordingly, the Merger Agreement is included with this filing only to provide investors with information regarding
the terms of the Merger Agreement, and not to provide investors with any other factual information regarding the Company or its
business. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations
of the actual state of facts or condition of the Company or any of its affiliates. Moreover, information concerning the subject
matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may
or may not be fully reflected in the Company's public disclosures. The Merger Agreement should not be read alone, but should
instead be read in conjunction with the other information regarding the Company that is or will be contained in, or incorporated
by reference into, the annual, quarterly and current reports and other documents that the Company files or has filed with the Securities
and Exchange Commission.
The foregoing description of the Merger Agreement
and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by,
the full text of the Merger Agreement attached hereto as Exhibit 2.1, which is incorporated herein by reference.
Indemnification Agreements
On February 12, 2012, the Board of Directors
of the Company authorized the Company to enter into indemnification agreements in the form attached as Exhibit 10.1 hereto (the
"Indemnification Agreements") with each of its directors and its Interim President and Chief Executive Officer and
Chief Financial Officer.
Each Indemnification Agreement provides, among
other things, that, subject to the procedures set forth in the Indemnification Agreement: (i) the Company will indemnify the director
or officer in connection with any action, suit, arbitration, alternative dispute resolution proceeding, administrative hearing
or other proceeding arising after the date of the agreement as to which the director or officer is, was or is threatened to be
made a party (or is otherwise involved) by reason of such director's or officer's status as a director or officer of
the Company or in certain other capacities, to the fullest extent permitted by law; (ii) if requested by the director or officer,
and subject to specified exceptions, the Company will advance expenses to the director or officer in connection with any such proceeding;
(iii) if there is a change in control, upon the director's or officer's written election, the Company will seek the
advice of independent legal counsel with respect to whether such director or officer has met the applicable standard of conduct
to be entitled to indemnification under the Indemnification Agreement and such director's or officer's right to advancement
of expenses; and (iv) the rights of the director or officer under the Indemnification Agreement are in addition to any other rights
the director or officer may have under the Company's certificate of incorporation or by-laws or the General Corporation Law
of the State of Delaware or otherwise. In addition, each Indemnification Agreement establishes procedures regarding the defense
and settlement of claims by the parties, the relevant burden of proof and the period of limitations.
The foregoing summary of the Indemnification
Agreements is qualified in its entirety by reference to the full text of the form of Indemnification Agreement attached as Exhibit
10.1 hereto and incorporated by reference herein.
Cautionary Statement Regarding Forward-Looking Statements
We caution you that this document may contain
disclosures that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about
the Company and the Merger. Forward-looking statements include statements in which we use words such as "expect," "believe,"
"anticipate," "intend," or similar expressions. These forward-looking statements are based upon information
presently available to the Company's management and are inherently subjective, uncertain and subject to change, due to any
number of risks and uncertainties. Factors that could cause events not to occur as expressed in the forward-looking statements
in this document include, but are not limited to, unanticipated delays; the occurrence of any event, change or other circumstances
that could give rise to the termination of the Merger Agreement; the outcome of any legal proceedings that may be instituted with
respect to the Merger; and the inability to complete the Merger due to the failure to obtain the Shareholder Approval or the failure
to satisfy other closing conditions, including the receipt of required regulatory approvals, as well as other risk factors detailed
in the Company's Annual Report on Form 10-K filed with the SEC on November 21, 2011, as amended, under the captions "Cautionary
Note Regarding Forward-Looking Statements" and "Risk Factors" and otherwise in the Company's reports and
filings with the Securities and Exchange Commission. Many of these factors are beyond the Company's ability to control or
predict. You should not place undue reliance on any forward-looking statements, since those statements speak only as of the date
that they are made. The Company assumes no obligation to update, revise or correct any forward-looking statements after the date
of this document or after the respective dates on which such statements otherwise are made, whether as a result of new information,
future events or otherwise, except as otherwise may be required by law.
Additional Information about the Merger and Where to Find
It
This document may be deemed to be solicitation
material with respect to the Merger. In connection with the Merger, the Company intends to file a preliminary proxy statement and
file or furnish other relevant materials with the Securities and Exchange Commission, or the SEC. Once the SEC completes its review
of the preliminary proxy statement, a definitive proxy statement and a form of proxy will be filed with the SEC and mailed to the
shareholders of the Company. THE COMPANY'S INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY
ALL RELEVANT MATERIALS FILED OR FURNISHED WITH THE SEC, INCLUDING THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE, BECAUSE THESE
MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE MERGER. The proxy statement and other
relevant materials (when they become available), and any and all documents filed or furnished by the Company with or to the SEC,
may be obtained free of charge at the SEC's web site at www.sec.gov. In addition, the Company's investors and security
holders may obtain free copies of the documents filed or furnished by the Company with or to the SEC by directing a written request
to SeraCare Life Sciences, Inc., 37 Birch Street, Milford, MA 01757, Attention: Corporate Secretary.
Participants in the Solicitation
The Company and its executive officers and directors
may be deemed to be participants in the solicitation of proxies from the shareholders of the Company with respect to the special
meeting of shareholders that will be held to consider the Merger. Information about those executive officers and directors of the
Company and their ownership of the Company's common stock is set forth in Amendment No. 1 to the Company's Annual Report
on Form 10-K for the fiscal year ended September 30, 2011, which was filed with the SEC on January 30, 2012, and is supplemented
by other public filings made, and to be made, with the SEC by the Company. Information regarding the direct and indirect interests
of the Company, its executive officers and directors and other participants in the solicitation, which may, in some cases, be different
from those of the Company's security holders generally, will be set forth in the proxy statement relating to the Merger when
it becomes available.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
.
Exhibit No.
Description
2.1
Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc.*
10.1
Form of Indemnification Agreement with members of the Board of Directors and the Interim President and Chief Executive Officer and Chief Financial Officer
__________________________________
* Schedules have been omitted pursuant to Item 601(b)(2) of Regulation
S-K. SeraCare Life Sciences, Inc. hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request
by the SEC.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SERACARE LIFE SCIENCES, INC.
By:
/s/ Gregory A. Gould
Name: Gregory A. Gould
Title:   Interim President and Chief
Executive
Officer, Chief Financial Officer,
Secretary
and Treasurer
Dated: February 14, 2012
EXHIBIT INDEX
Exhibit No.
Description
2.1
Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc.*
10.1
Form of Indemnification Agreement with members of the Board of Directors and the Interim President and Chief Executive Officer and Chief Financial Officer
* Schedules have been omitted pursuant to Item 601(b)(2) of Regulation
S-K. SeraCare Life Sciences, Inc. hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request
by the SEC.